[1] Ahmad S. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes[J]. Chem Biodivers, 2010, 7(3): 543-566.  doi: 10.1002/cbdv.200800340
[2] Ren F, Chen R, Wang Y, et al. Paclitaxel-loaded poly(n-butylcyanoacrylate)nanoparticle delivery system to overcome multidrug resistance in ovarian cancer[J]. Pharm Res, 2011, 28(4): 897-906.  doi: 10.1007/s11095-010-0346-9
[3] Cao W, Shiverick K, Namiki K, el al.Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bel-2 expressing prostate cancer cells to irradiation[J]. World J Urol, 2008, 26(5): 509-516.  doi: 10.1007/s00345-008-0289-5
[4] Yoshida D, Ebara T, Sato Y, et al. Interaction of radiation and pemetrexed on a human malignant mesothlioma cell line in vitro[J]. Anticancer Res, 2011, 31(9): 2847-2851.
[5] Morgan MA, Parsels LA, Maybaum J, et al. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review[J]. Clin Cancer Res, 2008, 14(21): 6744-6750.  doi: 10.1158/1078-0432.CCR-08-1032
[6] Murphy JD, Lucas DR, Somnay YR, et al. Gemcitabine-mediated radiosensitization of human soft tissue sarcoma[J]. Transl Oncol, 2008, 1(1): 50-56.  doi: 10.1593/tlo.07121
[7] El Shafie RA, Habermehl D, Rieken S, et al. In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines[J]. J Radiat Res, 2013, 54 Suppl 1: S1113-1119.
[8] Yasui H, Ogura A, Asanuma T, et al. Inhibition of HIF-1alpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo[J]. Br J Cancer, 2008, 99(9): 1442-1452.  doi: 10.1038/sj.bjc.6604720
[9] Illum H. Irinotecan and radiosensitization in rectal cancer[J]. Anticancer Drugs, 2011, 22(4): 324-329.  doi: 10.1097/CAD.0b013e3283425c14
[10] Nam C, DoiK, Nakayaam H. Etoposide induces G2/M arrest and apoptosis in neural progenitor cells via DNA damage and all ATM/p53-related pathway[J]. Histol Histopathol, 2010, 25(4): 485-493.
[11] Griffin S, Walker S, Sculpher M, et al. Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck[J]. Health Technol Assess, 2009, 13 Suppl 1: S49-54.
[12] Stagno F, Vigneri P, Del Fabro V, et al. Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias[J]. Acta Oncol, 2010, 49(1): 109-110.
[13] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival[J]. Lancet Oncol, 2010, 11(1): 21-28.  doi: 10.1016/S1470-2045(09)70311-0
[14] Sato Y, Ebara T, Sunaga N, et al. Interaction of radiation and gefitinib on a human lung cancer cell line with mutant EGFR gene in vitro[J]. Anticancer Res, 2012, 32(11): 4877-4881.
[15] Rao K, Kalapurakal S, Chalasani P, et al. A phase Ⅱ study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer[J]. Cancer Chemother Pharmacol, 2013, 72(3): 545-552.  doi: 10.1007/s00280-013-2225-7
[16] Visentin M, Biason P, Toffoli G. Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents[J]. Pharmacol Ther, 2010, 128(1): 82-90.  doi: 10.1016/j.pharmthera.2010.05.005
[17] 李英杰, 于长海, 张文, 等. COX-2与LRP在非小细胞肺癌中的表达与肺癌预后的关系[J].临床肺科杂志, 2010, 15(12): 1707-1709.  doi: 10.3969/j.issn.1009-6663.2010.12.011
[18] Inoue T, Anai S, Onishi S, et al. Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model[J]. BMC Urol, 2013, 13: 1.  doi: 10.1186/1471-2490-13-1
[19] Koontz BF, Miles EF, Rubio MA, et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies[J]. Head Neck, 2008, 30(2): 262-266.  doi: 10.1002/hed.20674
[20] Viswanathan AN, Lee H, Berkowitz R, et al. A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer[J]. Gynecol Oncol, 2014, 132(1): 55-60.
[21] Harada H, Itasaka S, Zhu Y, et al. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy[J]. Br J Cancer, 2009, 100(5): 747-757.  doi: 10.1038/sj.bjc.6604939
[22] Tamatani T, Takamaru N, Hara K, et al. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells[J]. Int J Oncol, 2013, 42(3): 935-944.  doi: 10.3892/ijo.2013.1786
[23] Isebaert SF, Swinnen JV, McBride WH, et al. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells[J]. Int J Radiat Oncol Biol Phys, 2011, 81(1): 239-247.  doi: 10.1016/j.ijrobp.2011.03.030
[24] 吴冬梅, 杨荣宁.莪术油对鼻咽癌CNE-2细胞的凋亡及放疗增敏机制的影响[J].肿瘤防治研究, 2008, 11(35): 778-782.
[25] 曹远东, 孙新臣, 成红艳, 等.汉防己甲素配合放射线增敏治疗鼻咽癌的临床研究[J].东南大学学报, 2008, 27(2): 106-109.  doi: 10.3969/j.issn.1671-6264.2008.02.009
[26] 刘少龙, 罗辉, 谢淑华.三氧化二砷对胃癌细胞放射增敏作用的研究[J].江西医学院学报, 2009, 49(2): 47-50.  doi: 10.3969/j.issn.1000-2294.2009.02.012
[27] 汤继英, 潘东风, 石小燕, 等.三氧化二砷对人宫颈癌细胞的放射增敏作用[J].郧阳医学院学报, 2008, 27(2): 109-111.
[28] 谢良喜, 李德锐, 林英城, 等.三氧化二砷对鼻咽癌离体细胞的放射增敏作用[J].中华放射医学与防护杂志, 2004, 24(3): 240-242.  doi: 10.3760/cma.j.issn.0254-5098.2004.03.018
[29] 杨百霞, 杨曦, 朱琪伟, 等.盐酸小檗碱对乏氧食管癌细胞的放射增敏作用[J].中华放射医学与防护杂志, 2013, 33(5): 484-488.  doi: 10.3760/cma.j.issn.0254-5098.2013.05.007
[30] 王振华, 师国珍, 张宁, 等.去甲斑蝥素对肺癌A549细胞株体外放射增敏作用[J].中国实用医刊, 2009, 36(24): 8-10.  doi: 10.3760/cma.j.issn.1674-4756.2009.24.004
[31] 封阳, 周媛媛, 杨巍, 等.青蒿素联合60Co γ射线对HeIa和SiHa细胞所致DNA损伤的研究[J].苏州大学学报:医学版, 2011, 31(1): 2-5.
[32] 陈遐林, 曹建平, 纪蓉, 等.二氢青蒿素对人宫颈癌HeLa细胞放射增敏作用的研究[J].中华放射医学与防护杂志, 2009, 29(4): 360-363.  doi: 10.3760/cma.j.issn.0254-5098.2009.04.003
[33] 郭素敏, 宗会迁, 孙超英, 等.中药扶正联合放射治疗肺癌的临床研究[J].河北医药, 2008, 30(8): 1164 -1165.  doi: 10.3969/j.issn.1002-7386.2008.08.039
[34] 刘军叶, 郭鹞, 郭国祯. Bcl-2基因特异性小干涉RNA增强食管癌细胞辐射敏感性的实验研究[J].国际放射医学核医学杂志, 2006, 30(2): 110-113.  doi: 10.3760/cma.j.issn.1673-4114.2006.02.014